# ACADVL Deep Sequencing in a Case Study: Beyond the Common c.848T>C Pathogenic Variant

**Authors:** Francesco Baldo, Luisa Zupin, Andrea Magnolato, Valeria Capaci, Maria Teresa Bonati

PMC · DOI: 10.3390/genes16050538 · Genes · 2025-04-30

## TL;DR

A two-year-old girl with a mild form of VLCADD is studied to understand how genetic variants affect enzyme activity and disease risk.

## Contribution

The study identifies a hypomorphic ACADVL allele and demonstrates allelic imbalance in mRNA expression.

## Key findings

- The patient is compound heterozygous for ACADVL variants, including a novel synonymous substitution linked to reduced mRNA expression.
- Gene expression analysis revealed allelic imbalance and no abnormal isoform production.
- The c.957G>A variant is identified as a hypomorphic allele affecting VLCAD activity.

## Abstract

Background: Very-long-chain acyl-CoA dehydrogenase deficiency (VLCADD) is caused by biallelic pathogenic variants in ACADVL (acyl-CoA dehydrogenase very-long-chain), leading to impaired fatty acid oxidation and the accumulation of long-chain acylcarnitine. We report a single case of a two-year-old girl, whose neonatal metabolic screening revealed an acylcarnitine profile suggestive of VLCADD, with residual enzymatic activity of 19.8%. Methods: We performed ACADVL whole-gene sequencing. We then carried out an in silico analysis of the potential effects of the variants with dedicated tools, assessing splicing, RNA structure, RNA binding factors, and protein structure. We also conducted gene expression analysis. Results: Genetic testing identified her as compound heterozygous for the pathogenic ACADVL variant (NM_000018.3):c.848T>C, inherited from her mother, and for the two paternal variants, c.-64T>C in the basal promoter and c.957G>A, a synonymous substitution in exon 10. Gene expression analysis revealed reduced ACADVL mRNA levels in the proband’s blood cells but without abnormal isoform production. A decreased expression of the paternal allele carrying the 957A was also observed. Despite this significant reduction in mRNA levels, the underlying mechanism remains unclear. Conclusions: Although currently healthy, due to the VLCAD residual activity within the range associated with the mild form of the disease, the child might be at potential risk for metabolic decompensation or late-onset VLCADD. Our results indicated an allelic imbalance in mRNA expression and c.957G>A is identified as a hypomorphic allele. This suggests that deep ACADVL sequencing is a valuable tool for correlating genetic variants with enzymatic activity levels.

## Linked entities

- **Genes:** ACADVL (acyl-CoA dehydrogenase very long chain) [NCBI Gene 37]
- **Diseases:** Very-long-chain acyl-CoA dehydrogenase deficiency (MONDO:0008723), VLCADD (MONDO:0008723)

## Full-text entities

- **Genes:** ACADVL (acyl-CoA dehydrogenase very long chain) [NCBI Gene 37] {aka ACAD6, LCACD, VLCAD}
- **Diseases:** VLCADD (MESH:C536353)
- **Chemicals:** acylcarnitine (MESH:C116917), fatty acid (MESH:D005227)
- **Mutations:** 957A, c.-64T>C, c.848T>C

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12111055/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12111055/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12111055/full.md

---
Source: https://tomesphere.com/paper/PMC12111055